CalciMedica, Inc. (CALC): Nasdaq/NYSE listing notice — Graybug Vision receives Nasdaq notice for non-compliance with $1.00 minimum bid price; 180-day cure ends June 26, 2023

CalciMedica, Inc.

Closing bid price below $1.00 for 30 consecutive trading days as of December 27, 2022.
Initial compliance period of 180 calendar days, until June 26, 2023, to regain compliance.
To cure, common stock must close at $1.00 or higher for at least 10 consecutive trading days.
Company may transfer to Nasdaq Capital Market for an additional 180-day period if criteria met.
No immediate impact on listing; Graybug is evaluating available options to address the deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CalciMedica, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

December 27, 2022, Graybug Vision, Inc. (“Graybug” or the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the last 30 consecutive trading days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CalciMedica, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-313722

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.